The mechanisms of @entity229 @entity32 in @entity30 involve changes in intestinal permeability, mucosal XXXX production and nuclear factor kappa B expression.

@entity1 @entity2656 @entity32 @entity2451 @entity310 @entity229 @entity4284 @entity30
BACKGROUND: The clinical course of @entity30 after the induction of remission with medical therapy is characterized by unpredictable relapse. AIM: To evaluate three surrogate markers, intestinal permeability, mucosal @entity310 and nuclear factor (NF)-kappaB/ @entity4284 expression, in order to determine the relationship of these parameters to clinical relapse. METHODS: Thirty @entity1 with active @entity30 were treated with a 10 week course of @entity229 using a tapering dosing regimen. Intestinal permeability (lactulose/ @entity2656 [L/M ratio]) was determined at baseline and at the end of @entity229 tapering. @entity310 production and the levels of expression of @entity2451 / @entity4284 were measured in colonic mucosal biopsies obtained after the induction of remission. RESULTS: Twenty-two @entity1 (73%) achieved remission and 50% of @entity1 experienced a clinical relapse during the ensuing 12 months. Treatment with @entity229 resulted in a significant decrease in the L/M ratio. Of the @entity1 that relapsed, 75% had a raised L/M ratio at the time of remission compared with 20% of @entity1 with a normal L/M ratio (P < 0.008; hazard ratio = 6.094; CI 1.55, 17.43). Mucosal @entity310 production was greater in relapsers compared with those who remained in remission. The levels of @entity2451 in relapsers were significantly greater and levels of cytosolic @entity4284 were significantly lower compared with those measured in @entity1 who remained in remission. CONCLUSIONS: These findings underscore the importance of incorporating biological parameters of @entity32 in determining the clinical course of @entity30 .
